BUSINESS
Short Call: Time to book profits in capex? Morgan's bull case for cement, D-Mart, Varun Bev, HCL Tech, Nestle in focus
“Missing the bottom on the way up won't cost you anything. It's missing the top on the way down that's always expensive.” - Peter Lynch
BUSINESS
Godrej Agrovet on a turnaround journey; solid earnings, growth prospects spark bullishness
Godrej Agrovet has shown a turnaround in its crop protection business. That's not all, the other verticals of the company are also expected to move towards market-leading positions in the coming years.
BUSINESS
Ambuja Cements surges 3% after Nomura's double upgrade to 'buy'
Nomura cited Ambuja's aggressive capacity expansion, industry leading volume growth and value accretive acquisitions as the drivers behind the upgrade.
BUSINESS
Analyst Call Tracker: Tata Motors emerges as top bet in auto sector, rival Maruti Suzuki sees downgrades
Tata Motors leads sector upgrades in June with plans to demerge, focusing on PV growth and global markets, while Maruti Suzuki faces downgrades amid concerns over premiumisation and increasing competition.
BUSINESS
Analyst Call Tracker: Caution continues for IT stocks despite recent upgrades
Analysts remain cautious on IT stocks like Wipro, Tech Mahindra, and HCLTech despite some signs of recovery ahead of the Q1 earnings season. Persistent challenges such as tightened US spending and an uncertain macro environment continue to temper expectations.
BUSINESS
Analyst Call Tracker | Brokerages fall out of love with Dr Reddy's, caution spreads over recent acquisition
Despite pessimism from analysts, investors continued to lap up shares of Dr Reddy's in the past month, lifting the stock nearly 7 percent higher during the tenure.
BUSINESS
Lupin stock jumps 8% after Kotak Institutional Equities' double upgrade to 'add'
Kotak believes that Lupin has a bunch of great products lined up, which will ensure a remarkable year for the company's US sales in FY26.
BUSINESS
Wockhardt shares skyrocket nearly 40% in five days as two crucial antibiotics inch closer to launch
Two of Wockhardt's investigational antibiotics— Nafithromycin for treating pneumonia and Zaynich for urinary tract infection are nearing their probable launches, driving the sentiment for the drugmaker. Both the drugs offer a multi-million dollar opportunity for Wockhardt, showcasing the company's R&D prowess.
BUSINESS
US FDA's warning letter to Sun Pharma's Dadra unit highlights multiple repeat observations
The US drug regulator had inspected Sun Pharma's Dadra unit back in December 4-15 last year, following which, it classified the facility as 'Official Action Indicated.'
BUSINESS
Dr Reddy's Labs stock gains 3% on plans to acquire Haleon's nicotine replacement biz
Despite high anticipation for an acquisition by Dr. Reddy's, the company's decision to acquire Haleon's nicotine replacement portfolio has met with some skepticism from brokerages.
BUSINESS
100% up and accumulating: What makes HDFC MF so bullish on Sudarshan Chemical stock
One of India’s finest fund managers is accumulating a stock that is up 100 percent in 15 months and trading near its peak.
BUSINESS
Analyst Call Tracker: Sun Pharma faces slew of downgrades on concerns over earnings moderation
Brokerages foresee near-term challenges for Sun Pharma due to increased R&D costs and tax rates impacting earnings in FY25, but remain positive about its long-term outlook.
BUSINESS
Defensives FMCG, pharma, IT may gain as investors on backfoot after weak mandate for NDA
With the lack of expected political continuity after BJP's not-so-thumping win, investors shifted bets towards FMCG, pharma and IT stocks, typically seen as defensive plays.
BUSINESS
The final tally: Stocks that gained the most in the election rally
From being the darlings of D-Street to concerns over stretched valuations prompting bearish outlook, BJP's smaller-than-expected victory stole the sheen out of PSU, railways, defence and construction stocks.
BUSINESS
Market headed for multi-week rally as exit polls predict big win for BJP
The sharp spike in FIIs' short bets in the Indian derivatives market ahead of the exit polls has created a trade setup that positions the market in a multi-week upward rally, believes Rohit Srivastava of Indiacharts.
BUSINESS
Apollo Hospitals' healthy Q4 earnings, brokerages cheer upbeat management guidance
Apollo's has guided to deliver 15 percent growth and 68-70 percent occupancy for its core hospital business in FY25. The firm also aims to achieve EBITDA breakeven for its 24/7 business in the next 6-8 quarters.
BUSINESS
Apollo Hospitals aims at mid-teen growth for core business in FY25
Apollo Hospitals plans to focus on lifting volumes, cost optimisation, and expanding international patient base. These steps, aimed at improving occupancy levels should also drive earnings growth.
BUSINESS
Apollo Hospitals rises 3% as investors cheer robust Q4 results
Apollo's online arm, Apollo HealthCo, which was a major drag on the company's earnings in recent quarters, turned EBITDA positive in Q4 FY24 as previously guided by the management.
BUSINESS
Apollo Hospitals Q4 preview: Steady hospital business, healthy growth in HealthCo to aid earnings expansion
Improved performance from Apollo Hospitals' online business, Apollo HealthCo, and strong seasonality for its flagship hospital business is expected to drive earnings growth in Q4.
BUSINESS
Glenmark Pharma hits 52-week high on double-digit FY25 earnings growth target
Glenmark Pharma soared as management's bullish FY25 targets offset weak quarterly earnings. Despite widening losses due to impairment charges, adjusted net profit nearly tripled, driven by a stake sale in Glenmark Life Sciences.
BUSINESS
Torrent Pharma stock hits record high as strong Q4 results trigger bullishness across brokerages
Despite some concerns over stock valuations, brokerages remain bullish on the company's potential for further growth driven by strong Q4FY24 earnings and positive management commentary.
BUSINESS
Divi's Labs' better-than-expected Q4 results trigger slew of price target upgrades
Despite brokerages raising price targets for Divi's Labs following its robust performance in Q4, they maintained neutral recommendations on the stock. Their rationale lies in the belief that the current stock valuations already the current stock valuations factor in much of its growth prospects.
BUSINESS
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
The pharma company is expected to deliver decent earnings in Q4 FY24 aided by strong growth across its generics, nutraceuticals and custom synthesis businesses.
BUSINESS
RBI's Rs 2.1 lakh cr bonanza to govt brings cheer to stock market
RBI's dividend payout for FY24 was double what the government projected, hence, providing it with extra funds to ramp up capital expenditure, lower the fiscal deficit, or a mix of both.
